Analysts Offer Insights on Healthcare Companies: Inari Medical (NARI) and Axsome Therapeutics (AXSM)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Inari Medical (NARIResearch Report) and Axsome Therapeutics (AXSMResearch Report).

Inari Medical (NARI)

In a report released today, Travis Steed from Bank of America Securities maintained a Buy rating on Inari Medical, with a price target of $105.00. The company’s shares closed last Friday at $58.62, close to its 52-week low of $50.50.

According to, Steed is a 4-star analyst with an average return of 14.2% and a 57.9% success rate. Steed covers the Healthcare sector, focusing on stocks such as Tandem Diabetes Care, Baxter International, and Edwards Lifesciences.

Inari Medical has an analyst consensus of Strong Buy, with a price target consensus of $88.33.

See Insiders’ Hot Stocks on TipRanks >>

Axsome Therapeutics (AXSM)

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Axsome Therapeutics on February 3 and set a price target of $86.00. The company’s shares closed last Friday at $68.70.

According to, Purohit is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -22.6% and a 18.9% success rate. Purohit covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Foghorn Therapeutics, and Kymera Therapeutics.

Currently, the analyst consensus on Axsome Therapeutics is a Strong Buy with an average price target of $109.30.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on NARI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More